Abstract:e15076 Background: Colorectal cancer (CRC) develops as a result of neoplastic progression, which often takes decades, providing a window for early detection. Unfortunately, there has been little success in developing blood-based screening method due to the low amount of ctDNA present in the circulation, especially in patients with early stage disease. The role of aberrant DNA methylation, occurring very early in tumorigenesis, has been well elucidated. In this prospective study, we evaluated the potentiality of DNA methylation status obtained from ctDNA as an early detection method. Methods: Panel Design: Methylation data of tumor samples (12 types, n = 4,772), adjacent normal (8 types, n = 411), and normal white blood cells (n = 656) from TCGA and GSE were compared. Differentially methylated sites were extracted using modified wald-test with an adjusted p-value 2. Our panel covers 80,672 CpG sites, spanning 1.05Mb of human genome. We performed targeted bisulfite sequencing on plasma samples of 67 (stage I: 13, II:29, III: 23, IV: 2) Chinese CRC patients and 144 healthy individuals to construct a model for deriving markers that are differentially methylated and their associated weight. The model was validated in 2 independent cohorts. Results: We constructed a model using a support vector machine (SVM)-based machine learning classifier based on top 4,000 differentially methylated regions (DMRs) selected by random forest between tumor and normal plasma samples. Subsequently, 5-fold cross-validation with 100-time repeats were performed to gain a robust estimation of model performance, achieving a sensitivity of 91%, specificity of 98% and area under curve (AUC) of 98.6%. The model was subsequently validated in 2 independent cohorts: one consisted of 57 stage I-III CRC patients and 74 healthy individuals and another one with 47 stage IV patients and the same 74 healthy individuals. The model yielded a sensitivity of 83% and 95% for the early and late stage cohorts, respectively. A specificity of 95% was obtained for both cohorts. Conclusions: Our findings demonstrated the potential of profiling DNA methylation, which can effectively distinguish cancerous from healthy, for the purpose of screening. This method has potential to serve as a supplementary or alternative approach in early detection.

Screening of Breast Cancer Methylation Biomarkers Based on the TCGA Database

Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients

A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions

Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers

DNA Methylation Markers for Diagnosis and Prognosis of Common Cancers.

Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis

Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients

Whole‐genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer

Identifying Methylation Pattern And Genes Associated With Breast Cancer Subtypes

Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis

DNA methylation profiling from circulating tumor DNA for early-detection of colorectal cancer.

Discovered Key CpG Sites by Analyzing DNA Methylation and Gene Expression in Breast Cancer Samples

Identification and Validation of Colorectal Neoplasia-Specific Methylation Biomarkers Based on CTCF-binding Sites

Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer

Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers

Construction of DNA methylation-based biomarkers for diagnosis of hepatocellular carcinoma.

Value of altered methylation patterns of genes RANBP3, LCP2 and GRAP2 in cfDNA in breast cancer diagnosis

Aberrant Promoter Methylation of Cancer-Related Genes in Human Breast Cancer

Whole-genome DNA methylation and DNA methylation-based biomarkers in lung squamous cell carcinoma

Clinical signiifcance of BRCA1, GSTP1 and MGMT gene methylation status in breast cancer

Microarray-based analysis of whole-genome DNA methylation profiling in early detection of breast cancer.